Welcome to LookChem.com Sign In|Join Free
  • or
3-(tert-butoxycarbonyl)-2,2-dimethyloxazolidine-4-carboxylic acid is a chemical compound that is commonly used in organic synthesis and pharmaceutical research. It is a derivative of oxazolidine-4-carboxylic acid, containing a tert-butoxycarbonyl protecting group on the nitrogen atom and two methyl groups on the carbon atom. 3-(tert-butoxycarbonyl)-2,2-dimethyloxazolidine-4-carboxylic acid is important in the production of various drugs and pharmaceutical intermediates due to its ability to selectively protect certain functional groups during chemical reactions. Additionally, its structural features make it useful for the development of new molecules with potential biological activity. Overall, 3-(tert-butoxycarbonyl)-2,2-dimethyloxazolidine-4-carboxylic acid plays a key role in the advancement of medicinal chemistry and drug discovery.

301155-28-2

Post Buying Request

301155-28-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

301155-28-2 Usage

Uses

Used in Pharmaceutical Industry:
3-(tert-butoxycarbonyl)-2,2-dimethyloxazolidine-4-carboxylic acid is used as a protecting group in the synthesis of various drugs and pharmaceutical intermediates. Its ability to selectively protect functional groups during chemical reactions allows for the development of complex molecules with specific biological activities.
Used in Medicinal Chemistry Research:
3-(tert-butoxycarbonyl)-2,2-dimethyloxazolidine-4-carboxylic acid is used as a building block in the design and synthesis of new molecules with potential therapeutic applications. Its unique structural features enable the creation of novel compounds that can be further optimized for improved biological activity and selectivity.
Used in Drug Discovery:
3-(tert-butoxycarbonyl)-2,2-dimethyloxazolidine-4-carboxylic acid is used as a key component in the development of new drugs and drug candidates. Its versatility in protecting functional groups and its potential to be incorporated into various molecular frameworks make it an invaluable tool in the drug discovery process.

Check Digit Verification of cas no

The CAS Registry Mumber 301155-28-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,1,1,5 and 5 respectively; the second part has 2 digits, 2 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 301155-28:
(8*3)+(7*0)+(6*1)+(5*1)+(4*5)+(3*5)+(2*2)+(1*8)=82
82 % 10 = 2
So 301155-28-2 is a valid CAS Registry Number.

301155-28-2Relevant academic research and scientific papers

Capturing Intermediates in the Reaction Catalyzed by NosN, a Class C Radical S-Adenosylmethionine Methylase Involved in the Biosynthesis of the Nosiheptide Side-Ring System

Wang, Bo,Lamattina, Joseph W.,Marshall, Savannah L.,Booker, Squire J.

supporting information, (2019/04/17)

Nosiheptide is a ribosomally synthesized and post-translationally modified thiopeptide natural product that possesses antibacterial, anticancer, and immunosuppressive properties. It contains a bicyclic structure composed of a large macrocycle and a unique

Capturing Intermediates in the Reaction Catalyzed by NosN, a Class C Radical S-Adenosylmethionine Methylase Involved in the Biosynthesis of the Nosiheptide Side-Ring System

Wang, Bo,Lamattina, Joseph W.,Marshall, Savannah L.,Booker, Squire J.

supporting information, p. 5788 - 5797 (2019/04/17)

Nosiheptide is a ribosomally synthesized and post-translationally modified thiopeptide natural product that possesses antibacterial, anticancer, and immunosuppressive properties. It contains a bicyclic structure composed of a large macrocycle and a unique

[4-(1, 3, 3-TRIMETHYL-2-OXO-3, 4-DIHYDRO-1H-QUINOXALIN-7-YL) PHENOXY]ETHYLOXY COMPOUND OR SALT THEREOF

-

Paragraph 0123; 0125, (2018/07/29)

The present invention relates to a novel [4-(1,3,3-trimethyl-2-oxo-3,4-dihydro-1H-quinoxalin-7-yl)phenoxy]ethyloxy compound or a salt thereof. The compound or a salt thereof of the present invention has a glucocorticoid receptor agonist activity, and is u

Total synthesis of the azolemycins

Anderson, Zoe J.,Fox, David J.

supporting information, p. 1450 - 1454 (2016/02/03)

The first total syntheses of newly isolated polyazole natural products azolemycins A-D, along with the synthesis of the tetra-oxazole non-natural analogue, are described.

ISOINDOLINE COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE

-

, (2015/09/23)

Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta- associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated membrane trafficking change in neuronal cells, and treating cognitive decline associated with Abeta pathology are provided.

BROMODOMAIN-INHIBITING COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING A CANCER

-

Page/Page column 23; 25; 26, (2015/11/27)

Provided is a novel compound having bromodomain and extra terminal domain (BET) protein inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of precancerous transformation or cancer.

Hepatitis C Virus Inhibitors

-

Paragraph 1778-1779, (2015/02/25)

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS

-

Page/Page column 593; 594, (2015/02/02)

The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.

Synthesis of a novel series of 2,3,4-trisubstituted oxazolidines designed by isosteric replacement or rigidification of the structure and cytotoxic evaluation

Andrade, Saulo F.,Teixeira, Claudia S.,Ramos, Jonas P.,Lopes, Marcela S.,Pdua, Rodrigo M.,Oliveira, Mnica C.,Souza-Fagundes, Elaine M.,Alves, Ricardo J.

supporting information, p. 1693 - 1699 (2014/12/11)

We have previously reported on a study of the structure-activity relationship in a series of 2,3,4-substituted oxazolidines recently discovered by our group varying the substituent at the ring or stereochemistry of the oxazolidine ring. We discovered the cytotoxic and pro-apoptotic potential of compounds 1 and 2 with good selectivity against cancer cell lines. In the present study we describe the synthesis and cytotoxic evaluation against cancer cell lines (HL60, JURKAT, MDA-MB-231 and LNCaP) of a series of oxazolidines designed by isosteric replacement or rigidification of the oxymethylene spacer of compounds 1 and 2. Alkenes 3 and 4 retained the activity against MDA-MB-231 cells and they were more active on HL60, JURKAT and LNCaP cells. Considering LNCaP cells, E-isomer 4 was at least 7 times and about 3 times more potent than lead 1 and Z-isomer 3, respectively. Compound 4 exerted significant activity against LNCaP with IC50 in the low micromolar range (11 μM) without affecting VERO cells and PBMC proliferation (IC50 > 100 μM) indicating its low toxicity to normal cells.

NMR characterization and conformational analysis of a potent papain-family cathepsin L-like cysteine protease inhibitor with different behaviour in polar and apolar media

Rotondo, Archimede,Ettari, Roberta,Zappalà, Maria,De Micheli, Carlo,Rotondo, Enrico

, p. 337 - 343 (2015/01/16)

We recently reported the synthesis, of a potent papain-family cathepsin L-like cysteine protease inhibitor, as new lead compound for the development of new drugs that can be used as antiprotozoal agents. The investigation of its conformational profile is

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 301155-28-2